Nrx pharmaceuticals announces fda clearance of its investigational new drug (ind) application for nrx-101 in the treatment of complicated urinary tract infections

"study may proceed" letter received from fda potential to initiate registrational study in 2024 radnor, pa. , dec. 18, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company today announced that its investigational new drug application (ind) for the use of nrx-101, the company's patented combination of d-cycloserine and lurasidone, for the treatment of complicated urinary tract infections (cuti), received clearance from the us fda.
NRXP Ratings Summary
NRXP Quant Ranking